Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-1130P is a human pseudogene cloned from the U6 small nuclear RNA (snRNA) gene family. U6 snRNAs are highly conserved non-coding RNAs essential for the function of the spliceosome, which catalyzes the excision of introns from pre-mRNA in eukaryotes[1][3]. However, the '1130 pseudogene' variant is a nonfunctional, processed pseudogene, meaning it arose via retrotransposition and lacks the ability to produce an active snRNA molecule[2][5]. Unlike canonical U6 snRNA, this pseudogene is not transcribed into a functional RNA and does not participate in RNA splicing, gene regulation, or any other biological mechanism. There is no evidence that RNU6-1130P or similar U6 pseudogenes play any role in disease, signaling, or represent viable drug targets[2]. Pseudogenes like this are numerous in the human genome and primarily serve as evolutionary remnants, occasionally useful for studying retrotransposition dynamics, but not as bona fide molecular targets[2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on U6 small nuclear RNA 1130, pseudogene (RNU6-1130P).